<table data-role="table"  data-mode="columntoggle" class="ui-responsive table-stroke">
<tbody>
<tr >
<td><strong>Discontinue immediately if patient receives a positive HIV test result</strong>
<ul class="single">
<li>Refer and link to HIV care and obtain genotypic testing</li>
</ul><br />
</td>
</tr>
<tr>
<td><em><u class="single">Important Note</u></em>: Discontinuation of TDF/FTC in patients with chronic active hepatitis B virus can cause exacerbations of hepatitis B.<br /><br /></td>
</tr>
<tr>
<td><strong>Discontinue in patients who:</strong>
<ul class="single">
<li>develop renal disease</li>
<li>are non-adherent to medication or appointments after attempts to improve adherence</li>
<li>are using medication for purposes other than intended</li>
<li>reduce risk behaviors to the extent that PrEP is no longer needed</li>
<li>request discontinuation, with referral to risk-reduction support services and documentation of referral</li>
</ul>
<p><em><u>Note</u>: For women who become pregnant while using PrEP, continuation of PrEP during pregnancy is an individualized decision based on whether there are ongoing risks for HIV during pregnancy.</em></p></td>
</tr>
</tbody>
</table>
